Argenx
ARGX
#459
Rank
HK$408.77 B
Marketcap
HK$6,606
Share price
-0.63%
Change (1 day)
30.25%
Change (1 year)
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.

EPS for Argenx (ARGX)

EPS in 2025 (TTM): HK$68.96

According to Argenx 's latest financial reports the company's current EPS (TTM) is HK$69.30. In 2024 the company made an earnings per share (EPS) of HK$108.75 an increase over its 2023 EPS that were of -HK$40.31.

EPS history for Argenx from 2011 to 2025

Annual EPS

Year EPS Change
2025 (TTM)HK$68.96-36.59%
2024HK$108.75-369.77%
2023-HK$40.31-60.46%
2022-HK$101.9563.33%
2021-HK$62.42-40.37%
2020-HK$104.69183.47%
2019-HK$36.93123.09%
2018-HK$16.5554.93%
2017-HK$10.6814.07%
2016-HK$9.3713.05%
2015-HK$8.29-36.34%
2014-HK$13.01209.04%
2013-HK$4.21-33.99%
2012-HK$6.38185.59%
2011-HK$2.23